Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Early Phase 1
1(50.0%)
Phase 2
1(50.0%)
2Total
Early Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06245213Phase 2Active Not Recruiting

A Study of ANAVEX3-71 in Adults With Schizophrenia

Role: collaborator

NCT04928703Early Phase 1Completed

Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers

Role: collaborator

NCT04025502Completed

Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects

Role: collaborator

All 3 trials loaded